Buy Aurobindo Pharma, target Rs 1050: BofA-ML
Sustained operational momentum was largely in line with our and consensus estimates. The US biz growth on new launches in the oral and injectable segment and Natrol is a positive sign.
By 
| Updated:
| Updated: BofA-ML maintains a buy rating on Aurobindo Pharma post March quarter results with a 12-month target price of Rs 1050.
Sustained operational momentum was largely in line with our and consensus estimates. The US biz growth on new launches in the oral and injectable segment and Natrol is a positive sign.
The EBITDA margins came at 23.5%. The miss was largely on account of higher R&D. Actavis turns profitable during the year led by product pruning and cost efficiencies, said the global investment bank.
Sustained operational momentum was largely in line with our and consensus estimates. The US biz growth on new launches in the oral and injectable segment and Natrol is a positive sign.
The EBITDA margins came at 23.5%. The miss was largely on account of higher R&D. Actavis turns profitable during the year led by product pruning and cost efficiencies, said the global investment bank.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
